Sign inCreate account

Report workspace tools

NCT04931862TERMINATEDanonymous

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-004 Administered Intrathecally to Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)

Sponsor

Source record

Wave Life Sciences Ltd.

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

WVE-004, Placebo

Indication / condition

AI-normalized

ALS

Intervention

Source record

WVE-004, Placebo

Source & freshness

Source record

NCT ID

NCT04931862

Original source

ClinicalTrials.gov

Source last updated

Oct 23, 2023

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04931862

Title

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-004 Administered Intrathecally to Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)

Sponsor

Wave Life Sciences Ltd.

Status

TERMINATED

Phase

PHASE1

Condition raw

ALS

Condition normalized

ALS

Modality raw

antisense oligonucleotide

Modality normalized

small molecule

Target raw

WVE-004, Placebo

Target normalized

WVE-004, Placebo

Interventions

WVE-004, Placebo

Public preview

Source record

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-004 Administered Intrathecally to Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) is a PHASE1 clinical asset sponsored by Wave Life Sciences Ltd. in ALS, FTD. SEO and diligence focus: WVE-004, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-004 Administered Intrathecally to Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04931862

Status

TERMINATED

Phase

PHASE1

Sponsor

Wave Life Sciences Ltd.

Executive brief

Investment-Ready Snapshot

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-004 Administered Intrathecally to Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) is a PHASE1 clinical asset sponsored by Wave Life Sciences Ltd. in ALS, FTD. SEO and diligence focus: WVE-004, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedOct 23, 2023
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04931862

Indication

ALS

Modality

small molecule

Target

WVE-004, Placebo

Intervention

WVE-004, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.